Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 2/20 | 0.48 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3309846 | 0.89 | ALDH1A1 (0.46) | PTGDR2KDM4EALDH1A1 | |
| SCHEMBL3314285 | 0.87 | PTGDR2 (0.39) | AKR1B1AKR1A1PTGDR2PTGS1MCL1 | |
| SCHEMBL3311492 | 0.85 | PTGDR2 (0.46) | AKR1B1PTGDR2PTGS1ALDH1A1 | |
| SCHEMBL3312910 | 0.83 | ALDH1A1 (0.39) | PTGDR2PTGS1KDM4EALDH1A1 | |
| SCHEMBL3313296 | 0.80 | CNR2 (0.42) | PTGDR2PTGS1KDM4EALDH1A1 | |
| SCHEMBL3311370 | 0.80 | CMA1 (0.44) | PTGDR2PTGS1KDM4EALDH1A1 | |
| SCHEMBL3316094 | 0.71 | AKR1A1 (0.51) | AKR1B1AKR1A1HDAC6KDM4E | |
| SCHEMBL18180179 | 0.68 | APEX1 (0.62) | AKR1B1AKR1A1PTGDR2KMOKDM4E | |
| SCHEMBL9045063 | 0.67 | ALDH1A1 (0.53) | AKR1B1AKR1A1PTGDR2HDAC6HDAC1 | |
| SCHEMBL10487904 | 0.66 | AKR1B1 (0.59) | AKR1B1AKR1A1PTGDR2HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140187550-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2014-07-03 | — | — | US | disclosed |
| US-8633211-B2 | Bicyclic organic compounds suitable for the treatment of inflammatory or allergic conditions | NOVARTIS AG (CH) | 2014-01-21 | — | — | US | disclosed |
| US-20100113774-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113774-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | S1PR3, S1PR1, S1PR2 | AKR1B1 674/4885AKR1A1 958/4885PTGDR2 95/4885 |
| US-20140187550-A1 | BICYCLIC ORGANIC COMPOUNDS SUITABLE FOR THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | S1PR3, S1PR1, S1PR2 | AKR1B1 520/4885AKR1A1 786/4885PTGDR2 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.